Methods for external control groups for single arm trials or long‐term uncontrolled extensions to randomized clinical trials
Purpose Clinical trials compare outcomes among patients receiving study treatment with comparators drawn from the same source. These internal controls are missing in single arm trials and from long‐term extensions (LTE) of trials including only the treatment arm. An external control group derived fr...
Gespeichert in:
Veröffentlicht in: | Pharmacoepidemiology and drug safety 2020-11, Vol.29 (11), p.1382-1392 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1392 |
---|---|
container_issue | 11 |
container_start_page | 1382 |
container_title | Pharmacoepidemiology and drug safety |
container_volume | 29 |
creator | Seeger, John D. Davis, Kourtney J. Iannacone, Michelle R. Zhou, Wei Dreyer, Nancy Winterstein, Almut G. Santanello, Nancy Gertz, Barry Berlin, Jesse A. |
description | Purpose
Clinical trials compare outcomes among patients receiving study treatment with comparators drawn from the same source. These internal controls are missing in single arm trials and from long‐term extensions (LTE) of trials including only the treatment arm. An external control group derived from a different setting is then required to assess safety or effectiveness.
Methods
We present examples of external control groups that demonstrate some of the issues that arise and make recommendations to address them through careful assessment of the data source fitness for use, design, and analysis steps.
Results
Inclusion and exclusion criteria and context that produce a trial population may result in trial patients with different clinical characteristics than are present in an external comparison group. If these differences affect the risk of outcomes, then a comparison of outcome occurrence will be confounded. Further, patients who continue into LTE may differ from those initially entering the trial due to treatment effects. Application of appropriate methods is needed to make valid inferences when such treatment or selection effects are present.
Outcome measures in a trial may be ascertained and defined differently from what can be obtained in an external comparison group. Differences in sensitivity and specificity for identification or measurement of study outcomes leads to information bias that can also invalidate inferences.
Conclusion
This review concentrates on threats to the valid use of external control groups both in the scenarios of single arm trials and LTE of randomized controlled trials, along with methodological approaches to mitigate them. |
doi_str_mv | 10.1002/pds.5141 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7756307</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2461096908</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4191-71abae2d0afc5f8e006e6a63e432e8a23f5a7c56b6592aeef8a002a0bcac14833</originalsourceid><addsrcrecordid>eNp1kc1u1TAQhS0Eon9IPAGyxKabtHZiO8kGCRVoKxWBVFhbc53JrSvHvtgJpSyqPgLPyJPU6b2UH4nVWD5nvhnNIeQ5ZwecsfJw1aUDyQV_RLY5a9uCS1k_nt-yKhqp2i2yk9IlY1lrxVOyVZWtErlhm9y8x_EidIn2IVL8NmL04KgJfozB0WUM02qtJeuXDinEgY7Rgks0f7rglz9vf-SugU5-0-Wwuyf5ZINPdAw0gu_CYL9nwTjrrckj1pA98qTPBZ9t6i75_O7tp6OT4uzD8enR67PCCN7youawACw7Br2RfYOMKVSgKhRViQ2UVS-hNlItlGxLQOwbyGcBtjBguGiqape8WnNX02LAzmDeFJxeRTtAvNYBrP5b8fZCL8NXXddSVazOgP0NIIYvE6ZRDzYZdA48hinpUggpSsHUbH35j_UyTPNZZ5fK-aiWNb-BJoaUIvYPy3Cm51B1DlXPoWbriz-XfzD-SjEbirXhyjq8_i9If3xzfg-8Az65sG0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2461096908</pqid></control><display><type>article</type><title>Methods for external control groups for single arm trials or long‐term uncontrolled extensions to randomized clinical trials</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Seeger, John D. ; Davis, Kourtney J. ; Iannacone, Michelle R. ; Zhou, Wei ; Dreyer, Nancy ; Winterstein, Almut G. ; Santanello, Nancy ; Gertz, Barry ; Berlin, Jesse A.</creator><creatorcontrib>Seeger, John D. ; Davis, Kourtney J. ; Iannacone, Michelle R. ; Zhou, Wei ; Dreyer, Nancy ; Winterstein, Almut G. ; Santanello, Nancy ; Gertz, Barry ; Berlin, Jesse A.</creatorcontrib><description>Purpose
Clinical trials compare outcomes among patients receiving study treatment with comparators drawn from the same source. These internal controls are missing in single arm trials and from long‐term extensions (LTE) of trials including only the treatment arm. An external control group derived from a different setting is then required to assess safety or effectiveness.
Methods
We present examples of external control groups that demonstrate some of the issues that arise and make recommendations to address them through careful assessment of the data source fitness for use, design, and analysis steps.
Results
Inclusion and exclusion criteria and context that produce a trial population may result in trial patients with different clinical characteristics than are present in an external comparison group. If these differences affect the risk of outcomes, then a comparison of outcome occurrence will be confounded. Further, patients who continue into LTE may differ from those initially entering the trial due to treatment effects. Application of appropriate methods is needed to make valid inferences when such treatment or selection effects are present.
Outcome measures in a trial may be ascertained and defined differently from what can be obtained in an external comparison group. Differences in sensitivity and specificity for identification or measurement of study outcomes leads to information bias that can also invalidate inferences.
Conclusion
This review concentrates on threats to the valid use of external control groups both in the scenarios of single arm trials and LTE of randomized controlled trials, along with methodological approaches to mitigate them.</description><identifier>ISSN: 1053-8569</identifier><identifier>EISSN: 1099-1557</identifier><identifier>DOI: 10.1002/pds.5141</identifier><identifier>PMID: 32964514</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Inc</publisher><subject>Clinical trials ; external control ; long‐term extension (LTE) ; Patients ; pharmacoepidemiology ; real world data (RWD) ; single‐arm RCT</subject><ispartof>Pharmacoepidemiology and drug safety, 2020-11, Vol.29 (11), p.1382-1392</ispartof><rights>2020 The Authors. published by John Wiley & Sons Ltd.</rights><rights>2020 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd.</rights><rights>2020. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4191-71abae2d0afc5f8e006e6a63e432e8a23f5a7c56b6592aeef8a002a0bcac14833</citedby><cites>FETCH-LOGICAL-c4191-71abae2d0afc5f8e006e6a63e432e8a23f5a7c56b6592aeef8a002a0bcac14833</cites><orcidid>0000-0002-8020-3144</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpds.5141$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpds.5141$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32964514$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Seeger, John D.</creatorcontrib><creatorcontrib>Davis, Kourtney J.</creatorcontrib><creatorcontrib>Iannacone, Michelle R.</creatorcontrib><creatorcontrib>Zhou, Wei</creatorcontrib><creatorcontrib>Dreyer, Nancy</creatorcontrib><creatorcontrib>Winterstein, Almut G.</creatorcontrib><creatorcontrib>Santanello, Nancy</creatorcontrib><creatorcontrib>Gertz, Barry</creatorcontrib><creatorcontrib>Berlin, Jesse A.</creatorcontrib><title>Methods for external control groups for single arm trials or long‐term uncontrolled extensions to randomized clinical trials</title><title>Pharmacoepidemiology and drug safety</title><addtitle>Pharmacoepidemiol Drug Saf</addtitle><description>Purpose
Clinical trials compare outcomes among patients receiving study treatment with comparators drawn from the same source. These internal controls are missing in single arm trials and from long‐term extensions (LTE) of trials including only the treatment arm. An external control group derived from a different setting is then required to assess safety or effectiveness.
Methods
We present examples of external control groups that demonstrate some of the issues that arise and make recommendations to address them through careful assessment of the data source fitness for use, design, and analysis steps.
Results
Inclusion and exclusion criteria and context that produce a trial population may result in trial patients with different clinical characteristics than are present in an external comparison group. If these differences affect the risk of outcomes, then a comparison of outcome occurrence will be confounded. Further, patients who continue into LTE may differ from those initially entering the trial due to treatment effects. Application of appropriate methods is needed to make valid inferences when such treatment or selection effects are present.
Outcome measures in a trial may be ascertained and defined differently from what can be obtained in an external comparison group. Differences in sensitivity and specificity for identification or measurement of study outcomes leads to information bias that can also invalidate inferences.
Conclusion
This review concentrates on threats to the valid use of external control groups both in the scenarios of single arm trials and LTE of randomized controlled trials, along with methodological approaches to mitigate them.</description><subject>Clinical trials</subject><subject>external control</subject><subject>long‐term extension (LTE)</subject><subject>Patients</subject><subject>pharmacoepidemiology</subject><subject>real world data (RWD)</subject><subject>single‐arm RCT</subject><issn>1053-8569</issn><issn>1099-1557</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><recordid>eNp1kc1u1TAQhS0Eon9IPAGyxKabtHZiO8kGCRVoKxWBVFhbc53JrSvHvtgJpSyqPgLPyJPU6b2UH4nVWD5nvhnNIeQ5ZwecsfJw1aUDyQV_RLY5a9uCS1k_nt-yKhqp2i2yk9IlY1lrxVOyVZWtErlhm9y8x_EidIn2IVL8NmL04KgJfozB0WUM02qtJeuXDinEgY7Rgks0f7rglz9vf-SugU5-0-Wwuyf5ZINPdAw0gu_CYL9nwTjrrckj1pA98qTPBZ9t6i75_O7tp6OT4uzD8enR67PCCN7youawACw7Br2RfYOMKVSgKhRViQ2UVS-hNlItlGxLQOwbyGcBtjBguGiqape8WnNX02LAzmDeFJxeRTtAvNYBrP5b8fZCL8NXXddSVazOgP0NIIYvE6ZRDzYZdA48hinpUggpSsHUbH35j_UyTPNZZ5fK-aiWNb-BJoaUIvYPy3Cm51B1DlXPoWbriz-XfzD-SjEbirXhyjq8_i9If3xzfg-8Az65sG0</recordid><startdate>202011</startdate><enddate>202011</enddate><creator>Seeger, John D.</creator><creator>Davis, Kourtney J.</creator><creator>Iannacone, Michelle R.</creator><creator>Zhou, Wei</creator><creator>Dreyer, Nancy</creator><creator>Winterstein, Almut G.</creator><creator>Santanello, Nancy</creator><creator>Gertz, Barry</creator><creator>Berlin, Jesse A.</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8020-3144</orcidid></search><sort><creationdate>202011</creationdate><title>Methods for external control groups for single arm trials or long‐term uncontrolled extensions to randomized clinical trials</title><author>Seeger, John D. ; Davis, Kourtney J. ; Iannacone, Michelle R. ; Zhou, Wei ; Dreyer, Nancy ; Winterstein, Almut G. ; Santanello, Nancy ; Gertz, Barry ; Berlin, Jesse A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4191-71abae2d0afc5f8e006e6a63e432e8a23f5a7c56b6592aeef8a002a0bcac14833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Clinical trials</topic><topic>external control</topic><topic>long‐term extension (LTE)</topic><topic>Patients</topic><topic>pharmacoepidemiology</topic><topic>real world data (RWD)</topic><topic>single‐arm RCT</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Seeger, John D.</creatorcontrib><creatorcontrib>Davis, Kourtney J.</creatorcontrib><creatorcontrib>Iannacone, Michelle R.</creatorcontrib><creatorcontrib>Zhou, Wei</creatorcontrib><creatorcontrib>Dreyer, Nancy</creatorcontrib><creatorcontrib>Winterstein, Almut G.</creatorcontrib><creatorcontrib>Santanello, Nancy</creatorcontrib><creatorcontrib>Gertz, Barry</creatorcontrib><creatorcontrib>Berlin, Jesse A.</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Pharmacoepidemiology and drug safety</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Seeger, John D.</au><au>Davis, Kourtney J.</au><au>Iannacone, Michelle R.</au><au>Zhou, Wei</au><au>Dreyer, Nancy</au><au>Winterstein, Almut G.</au><au>Santanello, Nancy</au><au>Gertz, Barry</au><au>Berlin, Jesse A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Methods for external control groups for single arm trials or long‐term uncontrolled extensions to randomized clinical trials</atitle><jtitle>Pharmacoepidemiology and drug safety</jtitle><addtitle>Pharmacoepidemiol Drug Saf</addtitle><date>2020-11</date><risdate>2020</risdate><volume>29</volume><issue>11</issue><spage>1382</spage><epage>1392</epage><pages>1382-1392</pages><issn>1053-8569</issn><eissn>1099-1557</eissn><abstract>Purpose
Clinical trials compare outcomes among patients receiving study treatment with comparators drawn from the same source. These internal controls are missing in single arm trials and from long‐term extensions (LTE) of trials including only the treatment arm. An external control group derived from a different setting is then required to assess safety or effectiveness.
Methods
We present examples of external control groups that demonstrate some of the issues that arise and make recommendations to address them through careful assessment of the data source fitness for use, design, and analysis steps.
Results
Inclusion and exclusion criteria and context that produce a trial population may result in trial patients with different clinical characteristics than are present in an external comparison group. If these differences affect the risk of outcomes, then a comparison of outcome occurrence will be confounded. Further, patients who continue into LTE may differ from those initially entering the trial due to treatment effects. Application of appropriate methods is needed to make valid inferences when such treatment or selection effects are present.
Outcome measures in a trial may be ascertained and defined differently from what can be obtained in an external comparison group. Differences in sensitivity and specificity for identification or measurement of study outcomes leads to information bias that can also invalidate inferences.
Conclusion
This review concentrates on threats to the valid use of external control groups both in the scenarios of single arm trials and LTE of randomized controlled trials, along with methodological approaches to mitigate them.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Inc</pub><pmid>32964514</pmid><doi>10.1002/pds.5141</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-8020-3144</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1053-8569 |
ispartof | Pharmacoepidemiology and drug safety, 2020-11, Vol.29 (11), p.1382-1392 |
issn | 1053-8569 1099-1557 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7756307 |
source | Wiley Online Library Journals Frontfile Complete |
subjects | Clinical trials external control long‐term extension (LTE) Patients pharmacoepidemiology real world data (RWD) single‐arm RCT |
title | Methods for external control groups for single arm trials or long‐term uncontrolled extensions to randomized clinical trials |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T08%3A32%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Methods%20for%20external%20control%20groups%20for%20single%20arm%20trials%20or%20long%E2%80%90term%20uncontrolled%20extensions%20to%20randomized%20clinical%20trials&rft.jtitle=Pharmacoepidemiology%20and%20drug%20safety&rft.au=Seeger,%20John%20D.&rft.date=2020-11&rft.volume=29&rft.issue=11&rft.spage=1382&rft.epage=1392&rft.pages=1382-1392&rft.issn=1053-8569&rft.eissn=1099-1557&rft_id=info:doi/10.1002/pds.5141&rft_dat=%3Cproquest_pubme%3E2461096908%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2461096908&rft_id=info:pmid/32964514&rfr_iscdi=true |